Toggle Main Menu Toggle Search

Open Access padlockePrints

A phase II study of nilotinib a novel tyrosine kinase inhibitor administered to imatinib-resistant or intolerant patients with chronic myelogenous leukemia (CML) in accelerated phase (AP)

Lookup NU author(s): Professor Stephen O'Brien


Full text for this publication is not currently held within this repository. Alternative links are provided below where available.



Publication metadata

Author(s): Kantarjian HM, Gattermann N, Hochhaus A, Larson R, Rafferty T, Weitzman A, Haque A, Giles F, O'Brien SG, le Coutre P

Publication type: Conference Proceedings (inc. Abstract)

Publication status: Published

Conference Name: 48th Annual Meeting of the Annual Society of Hematology

Year of Conference: 2006

Pages: 615A-615A

Publisher: Blood: American Society of Hematology

Notes: Abstract 2169 Poster Board Session 347-II

Library holdings: Search Newcastle University Library for this item